Timeline
Last
$45.42
+5.50 (13.78%)
24HR+13.8%
1W+12.3%
1M+21.4%
1Y+119.2%
Valuation
- Market Cap
- $2.2B
- Enterprise Value
- $2B
- P/E (TTM)
- —
- Forward P/E
- 30.41x
- Price / Sales
- 15.75x
- EV / EBITDA
- -18.55x
Cash Flow
- Operating Cash Flow
- -$165.7M
- Free Cash Flow
- -$109.3M
- FCF Margin
- -77.8%
- Cash Conversion
- 65.9%
- Cash / Share
- $2.9
Margins & Growth
- Gross Margin
- 89.9%
- Operating Margin
- -39.8%
- EBITDA Margin
- -76.8%
- Net Margin
- -94.8%
- Revenue Growth
- 151.6%
- Earnings Growth
- —
Balance Sheet
- Total Cash
- $140.3M
- Total Debt
- $197.1M
- Net Cash
- -$56.8M
- Debt / Equity
- —
- Current Ratio
- 4.69x
- Quick Ratio
- 3.87x
Returns & Ownership
- Return on Assets
- -27.0%
- Return on Equity
- —
- Dividend Yield
- —
- Payout Ratio
- 0.0%
- Beta
- 1.57
- Institutional Ownership
- 101.8%
Latest EPS-$0.47+0.0% surprise
Beat rate25%1 print streak
Avg surprise-0.1%vs consensus
Next printAug 5, 2026EPS -$0.27
Quarterly EPS vs consensus
4 quarters Actual ConsensusLabels: beat $ · YoY %Revisions 20 up / 0 down
Earnings transcripts
Read management commentary and analyst Q&A.
No transcript dates are available yet for this ticker.
Forward estimates
Consensus expectations and estimate momentum.
PeriodEPSRevenueGrowth
0QJun 2026
-$0.27$63.5M+74.8%+1QSep 2026
-$0.05$75.6M+92.9%0YDec 2026
-$0.71$276.5M+77.9%+1YDec 2027
$1.49$435.3M+311.9%Primary research
Recent company filings
Jump directly to earnings releases, quarterly reports, and material updates.
8-KCorporate Changes & Voting Matters2026-08-058-KCorporate Changes & Voting Matters2026-06-238-KCorporate Changes & Voting Matters2026-06-028-KCorporate Changes & Voting Matters2026-05-0610-KPeriodic Financial Reports2026-03-028-KCorporate Changes & Voting Matters2025-08-278-KCorporate Changes & Voting Matters2025-08-078-KCorporate Changes & Voting Matters2025-07-038-KCorporate Changes & Voting Matters2025-06-138-KCorporate Changes & Voting Matters2025-05-1210-KPeriodic Financial Reports2025-03-108-KCorporate Changes & Voting Matters2025-02-20
URGN stock research · UroGen Pharma Ltd.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a…
| Last price | $45.4 |
|---|---|
| Day change | +5.50 (13.78%) |
| Market cap | $2.2B |
| P/E (TTM) | — |
| Sector | Healthcare |
| Industry | Biotechnology |